Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06840003 (EOS200271) is a specific and oral active IDO-1 inhibitor.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 9,000 | |||
5 mg | 在庫あり | ¥ 14,000 | |||
10 mg | 在庫あり | ¥ 19,500 | |||
25 mg | 在庫あり | ¥ 30,500 | |||
50 mg | 在庫あり | ¥ 42,000 | |||
100 mg | 在庫あり | ¥ 66,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 25,000 |
説明 | PF-06840003 (EOS200271) is a specific and oral active IDO-1 inhibitor. |
ターゲット&IC50 | IDO1 (human):0.41 μM, IDO1 (mouse):1.5 μM, dIDO1:0.59 μM |
In vitro | The s of PF-06840003 has inhibitory for hIDO-1 (IC50: 0.41 μM), mouse IDO-1 (IC50: 1.5 μM) and dog IDO-1 (IC50: 0.59 μM), respectively. It has very weak inhibitory against hTDO-2 (IC50: 140 μM). In cellular assays, PF-06840003 shows activity both in the LPS/INFγ-stimulated THP1 cells (IC50: 1.7 μM) and in the HeLa assay (IC50: 1.8 μM). PF-06840003 is a very weak inhibitory against CYPs (IC50>100 μM) except 2C19 (IC50: 78 μM). |
In vivo | In mice, PF-06840003 reduces intratumoral kynurenine levels (>80%). In multiple preClinicalal syngeneic models in mice, It inhibits tumor growth by combinated with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours. |
別名 | EOS200271, PF 06840003 |
分子量 | 232.21 |
分子式 | C12H9FN2O2 |
CAS No. | 198474-05-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (258.39 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-06840003 198474-05-4 Metabolism IDO Indoleamine 2,3-Dioxygenase (IDO) EOS-200271 EOS200271 PF 06840003 inhibit Inhibitor PF06840003 EOS 200271 inhibitor